Research Article| Volume 28, ISSUE 7, P609-619, October 01, 1990

Chronic lithium treatment prevents atropine-induced supersensitivity of the muscarinic phosphoinositide response in rat hippocampus

  • John Ellis
    Address reprint requests to John Ellis, Ph.D., Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT 05405.
    From the Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Search for articles by this author
  • Robert H. Lenox
    From the Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Search for articles by this author
  • Author Footnotes
    ∗ We thank Dr. Daniel Hendley, Joanne Huyler, and Ann Wood for excellent technical assistance and Claudette Laplume for manuscript preparation.
      This paper is only available as a PDF. To read, Please Download here.


      Rats were placed on a lithium diet for 3 weeks or an identical diet without lithium for the same period. During the third week, atropine sulfate (10 mg/kg/day) or saline was infused via subcutaneously implanted osmotic pumps. Twenty-four hours following the removal of the pumps, brain slices and membranes were prepared from the cortex and hippocampus for determination of muscarinic stimulation of phosphoinositide turnover and for receptor-binding studies. Treatment with lithium alone did not significantly affect any of the binding or response parameters measured. Administration of atropine led to (1) an upregulation of muscarinic binding sites in both cortex and hippocampus without significant alteration in the proportion of muscarinic receptor subtypes; and (2) an enhancement of the muscarinic phosphoinositide response in hippocampal slices. However, atropine did not induce supersensitivity of the hippocampal response in rats undergoing lithium administration. These results are consistent with recent suggestions that lithium's efficacy in affective disorders may be related to a dampening of musarinic supersensitivity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Allison J.H.
        • Blisner M.E.
        Inhibition of the effect of lithium on brain inositol by atropine and scopolamine.
        Biochem Biophys Res Commun. 1976; 68: 1332-1338
        • Ashkenazi A.
        • Peralta E.G.
        • Winslow J.W.
        • Ramachandran J.
        • Capon D.J.
        Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell.
        Cell. 1989; 56: 487-493
        • Avissar S.
        • Schreiber G.
        • Danon A.
        • Belmaker R.H.
        Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex.
        Nature. 1988; 331: 440-442
        • Berridge M.J.
        • Downes C.P.
        • Hanley M.R.
        Neural and developmental actions of lithium: A unifying hypothesis.
        Cell. 1989; 59: 411-419
        • Bunney W.E.
        • Garland B.L.
        Lithium and its possible modes of action.
        in: Post R.M. Ballenger J.C. Neurobiology of Mood Disorders. Williams & Wilkins, Baltimore1984: 731-743
        • Casebolt T.L.
        • Jope R.S.
        Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain.
        Biol Psychiatry. 1989; 25: 329-340
        • Costa L.G.
        • Kaylor G.
        • Murphy S.D.
        Carbachol- and norepinephrine-stimulated phosphoinositide metabolism in rat brain: Effect of chronic cholinesterase inhibition.
        J Pharmacol Exp Ther. 1986; 239: 32-37
        • Dilsaver S.C.
        Pathophysiology of “cholinoceptor supersensitivity” in affective disorders.
        Biol Psychiatry. 1986; 21: 813-829
        • Dilsaver S.C.
        • Coffman J.A.
        Cholinergic hypothesis of depression. A reappraisal.
        J Clin Psychopharmacol. 1989; 9: 173-179
        • Ellis J.
        Method for compairing selectivities of unlabeled subpopulation-selective ligands: Application to muscarinic receptors.
        J Receptor Res. 1988; 8: 885-900
        • Ellis J.
        • Huyler J.H.
        • Kemp D.E.
        • Weiss S.
        Muscarinic receptors and second-messenger responses of neurons in primary culture.
        Brain Res. 1990; 511: 234-240
        • Godfrey P.P.
        • McClue S.J.
        • White A.M.
        • Wood A.J.
        • Grahame-Smith D.G.
        Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex.
        J Neurochem. 1989; 52: 498-506
        • Goobar L.
        • Bartfai T.
        Long-term atropine treament lowers the efficacy of carbachol to stimulate phosphatidylinositol breakdown in the cerebral cortex and hippocampus of rats.
        Biochem J. 1988; 250: 727-734
        • Kafka M.
        • Wirz-Justice A.
        • Naber D.
        • Marangos P.
        • O'Donohue T.
        • Wehr T.
        Effect of lithium on circadian neurotransmitter receptor rhythms.
        Neuropsychobiology. 1982; 8: 41-50
        • Kendall D.A.
        • Nahorski S.R.
        Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex.
        J Pharmacol Exp Ther. 1987; 241: 1023-1027
        • Lee W.
        • Wolfe B.B.
        Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
        Mol Pharmacol. 1989; 36: 749-757
        • Lenox R.H.
        Role of receptor coupling to phosphoinositide metabolism in the therapeutic action of lithium.
        in: Ehrlich Y.H. Molecular Mechanisms of Neuronal Responsiveness. Plenum, New York1987: 515-530
        • Lenox R.H.
        • Hendley D.
        • Ellis J.
        Desensitization of muscarinic receptor-coupled phosphoinositide hydrolysis in rat hippocampus: Comparisons with the α1-adrenergic response.
        J Neurochem. 1988; 50: 558-564
        • Lerer B.
        • Stanley M.
        Effect of chronic lithium on cholinergically mediated responses and [3H]QNB binding in rat brain.
        Brain Res. 1985; 344: 211-219
        • Levy A.
        • Zohar J.
        • Belmaker R.H.
        The effect of chronic lithium pretreatment on rat brain muscarinic receptor regulation.
        Neuropharmacology. 1983; 21: 1199-1201
        • Liles W.C.
        • Nathanson N.M.
        Alteration in the regulation of neuronal muscarinic acetylcholine receptor number induced by chronic lithium in neuroblastoma cells.
        Brain Res. 1988; 439: 88-94
        • Maggi A.
        • Enna S.J.
        Regional alterations in rat brain neurotransmitter systems following chronic lithium treatment.
        J Neurochem. 1982; 34: 888-892
        • Thomas J.M.
        • Hoffman B.B.
        Agonist-induced down-regulation of muscarinic cholinergic and α2-adrenergic receptors after inactivation of Ni by pertussis toxin.
        Endocrinology. 1986; 119: 1305-1314
        • Thomsen K.
        The effect of sodium chloride on kidney function in rats with lithium intoxication.
        Acta Pharmacol Toxicol. 1973; 33: 92-102
        • Tollefson G.D.
        • Senogles S.
        A cholinergic role in the mechanism of lithium in mania.
        Biol Psychiatry. 1982; 18: 467-479
        • Watson M.
        • Roeske W.R.
        • Yamamura H.I.
        [3H]Pirenzepine and (−)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
        J Pharmacol Exp Ther. 1986; 237: 411-418